More than 2,000 XIENCE V Patients May Also Be Eligible to Join Industry-Wide Trial Studying Optimal Duration of Dual Anti-Platelet Therapy ABBOTT PARK, Ill., Aug. 13 (HSMN NewsFeed) — Abbott (NYSE: ABT ) today announced the expansion of the company’s…
Devices, Interventional Cardiology
Abbott, XIENCE V, Everolimus, drug eluting stent, anti-platelet
Posts on ‘August 13th, 2009’
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Constellation Pharmaceuticals, Inc. Appoints Mark A. Goldsmith, M.D., Ph.D. as CEO and Closes $17 Million in Funding
Company Big Emerging Field of Epigenetics CAMBRIDGE, Mass.–(HSMN NewsFeed)–Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human geno…
Biopharmaceuticals, Personnel, Venture Capital
Constellation Pharmaceuticals

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.